Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ChiCTR2600124944) titled 'Ropeginterferon Alfa-2b for High-Risk Smoldering Multiple Myeloma??' on May 19.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Peking Union Medical College Hospital
Condition:
Smoldering multiple myeloma (SMM)
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-05-30
Target Sample Size: Interferon treatment group:20;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=319670
Published by HT Digital Content Services with permission from Health Daily Digest....